Patent ID: 7968304

Claim:
A method of determining immunoresistance to botulinum toxin therapy in an individual, the method comprising the steps of: a) combining a BoNT/B peptide and a test sample under conditions suitable for the selective binding of the BoNT/B peptide to a neutralizing anti-BoNT antibody, the BoNT/B peptide having a length of at most 60 amino acids and comprising amino acids 1269-1281 of SEQ ID NO: 1 or amino acids 1268-1291 of SEQ ID NO: 1; and b) detecting the presence of a neutralizing anti-BoNT antibody-BoNT/B peptide complex, the neutralizing anti-BoNT antibody-BoNT/B peptide complex formed by the selective binding of the neutralizing anti-BoNT antibody and the BoNT/B peptide; wherein the presence of the neutralizing anti-BoNT antibody-BoNT/B peptide complex is indicative of immunoresistance to a BoNT therapy.